Pneumonia News

Treatment with vilobelimab reduced mortality at 28 to 60 days in patients with severe COVID-19 pneumonia without increasing infections, according to data presented at the European Respiratory Society International Congress.

Patients with normal oxygenation levels who were treated for possible pneumonia experienced similar outcomes with an “ultrashort” course of antibiotics compared with a longer course, researchers reported recently.

Undergoing preventive dental treatment within 12 months or periodontal treatment within 6 months of hospitalization was associated with a reduced risk for nonventilator hospital-acquired pneumonia, researchers found.

In a new study, ventilator-associated pneumonia-related mortality was higher among patients with COVID-19 compared with those without COVID-19, with more than 9% of overall mortality attributable to ventilator-associated pneumonia.

In a new study, data made available upon admission identified about 80% of patients with COVID-19 who had low-risk pneumonia.

Recurrent episodes of childhood bronchitis appear to be associated with increased risk for lung disease later in life, researchers reported in BMJ Open Respiratory Research.

Merck announced Wednesday that the FDA approved an expanded indication for Vaxneuvance, the company’s 15-valent pneumococcal conjugate vaccine, to include its use in infants and children aged 6 weeks to 17 years.

Patients with pneumonia who were admitted to hospitals with high readmission rates had an elevated risk for in-hospital adverse events, according to a study published in JAMA Network Open.

Among patients with COPD, mortality was higher after hospital admission with pneumonia compared with admission with COPD exacerbation, according to results published in the European Respiratory Journal.

An extended course of antibiotics showed no short-term clinical benefit for children hospitalized with community-acquired pneumonia compared with a standard, shorter course, a study found.